

## Appendix: Tables

1.	Sales January to December 2023 and 2022 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022 .....	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2023 vs. YTD December 2022.....	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe .....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International.....	10
9.	Roche Group consolidated income statement for the twelve months ended 31 December 2023 .....	11
10.	Roche Group core results reconciliation – Full Year 2023 .....	12
11.	Divisional core results reconciliation – Full Year 2023 .....	13
12.	Roche Group consolidated balance sheet .....	14
13.	Roche Group consolidated statement of cash flows.....	15

## 1. Sales January to December 2023 and 2022

CHF millions	Twelve months ended 31 December		% change	
	2023	2022	At CER	In CHF
Pharmaceuticals Division	44,612	45,551	6	-2
United States	23,606	23,322	8	1
Europe	8,306	8,143	6	2
Japan	3,745	4,949	-14	-24
International*	8,955	9,137	13	-2
Diagnostics Division	14,104	17,730	-13	-20
Roche Group	58,716	63,281	1	-7

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022

CHF millions	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022
Pharmaceuticals Div.	12,362	9	11,699	9	10,982	7	10,941	11	10,990	-2
United States	6,123	1	5,853	6	5,890	7	5,937	11	5,926	5
Europe	2,043	-3	2,071	5	2,034	5	2,154	9	2,047	3
Japan	1,920	69	1,390	18	820	8	727	1	808	-50
International*	2,276	4	2,385	13	2,238	6	2,123	17	2,209	16
Diagnostics Division	3,882	-9	3,623	-28	3,475	-17	3,333	-5	3,673	4
Roche Group	16,244	4	15,322	-3	14,457	0	14,274	7	14,663	0

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

### 3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD December 2023 vs. YTD December 2022

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	6,381	13	4,684	11	1,166	12	-	-	531	31
Hemlibra	4,147	16	2,493	14	845	18	373	12	436	29
Perjeta	3,768	1	1,336	-7	776	-8	215	4	1,441	16
Tecentriq	3,766	9	1,941	4	845	10	419	8	561	29
Actemra/RoActemra	2,630	5	1,223	9	775	0	311	3	321	4
Vabysmo	2,357	324	1,914	293	276	**	98	138	69	**
Xolair	2,176	5	2,176	5	-	-	-	-	-	-
Kadcyla	1,966	4	757	-2	577	-11	102	-12	530	43
MabThera/Rituxan	1,630	-15	987	-20	180	-9	24	-13	439	-6
Herceptin	1,626	-16	331	-26	353	-14	30	-33	912	-13
Avastin	1,573	-19	484	-19	98	-47	318	-26	673	-7
Alecensa	1,502	8	467	9	292	4	212	5	531	11
Evryssi	1,419	39	505	14	509	49	93	26	312	80
Activase/TNKase	1,173	6	1,112	6	-	-	-	-	61	5
Phesgo	1,120	64	423	48	534	52	4	-	159	189
Polivy	837	108	340	119	173	36	227	129	97	317
Gazyva	811	19	395	22	229	24	38	-14	149	18
Ronapreve	525	-65	-	-	5	-95	519	-60	1	-99
Lucentis	460	-52	460	-52	-	-	-	-	-	-
Pulmozyme	452	-10	303	-13	76	-18	1	8	72	9
Enspryng	256	49	69	37	18	111	153	43	16	180
Xofluza	90	49	12	-75	-	-	-	-	78	494

Rozlytrek	86	25	45	2	16	36	8	27	17	147
Lunsumio	58	**	50	-	8	188	-	-	-	-
Gavreto	55	120	25	21	6	58	-	-	24	**
Cotellic	50	14	22	61	11	-22	-	-	17	7
Luxturna	44	4	44	4	-	-	-	-	-	-
Columvi	28	-	20	-	8	-	-	-	-	-
Susvimo	3	54	3	54	-	-	-	-	-	-
Pharma other	3,623	-13	985	-24	530	-29	600	-5	1,508	0
Pharma total sales	44,612	6	23,606	8	8,306	6	3,745	-14	8,955	13

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%

#### 4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022
Ocrevus	1,609	18	1,636	14	1,564	15	1,567	12	1,614	9
Hemlibra	1,045	24	1,034	24	1,053	17	1,025	17	1,035	9
Perjeta	997	4	1,049	11	1,033	6	913	0	773	-11
Tecentriq	1,025	24	920	15	933	8	938	10	975	5
Actemra/RoActemra	662	-22	676	-12	620	2	647	21	687	13
Vabysmo	309	-	432	*	525	*	656	309	744	160
Xolair	583	6	479	5	552	4	570	3	575	7
Kadcyla	490	-3	509	5	492	-5	485	5	480	13
MabThera/Rituxan	479	-20	459	-17	423	-17	378	-13	370	-15
Herceptin	470	-22	477	-17	401	-22	383	-13	365	-14
Avastin	470	-25	416	-24	421	-17	373	-18	363	-15
Alecensa	386	10	372	9	386	11	368	7	376	7
Evrysdi	326	59	363	62	342	36	360	41	354	22
Activase/TNKase	296	-27	302	23	319	9	282	-4	270	-1
Phesgo	214	73	241	72	276	67	300	61	303	58
Polivy	147	97	150	96	203	129	252	144	232	74
Gazyva	191	9	197	24	205	20	213	22	196	12
Ronapreve	1,048	118	567	9	-17**	-98	-18**	-100	-7**	-100
Lucentis	212	-40	167	-35	132	-55	97	-53	64	-66
Pulmozyme	129	-15	127	-5	111	-15	104	-15	110	-6

\* Over 500%

\*\*Effect of currency revaluation (CHF/JPY) on CHF567m Q1 2023 Ronapreve sales

**5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States**

CHF millions	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022
Ocrevus	1,204	15	1,188	13	1,158	14	1,146	10	1,192	8
Hemlibra	632	21	631	21	616	14	615	15	631	8
Perjeta	398	13	392	8	371	6	338	-6	235	-35
Tecentriq	524	20	507	14	493	5	476	4	465	-4
Actemra/RoActemra	282	-42	296	-22	278	6	303	33	346	33
Vabysmo	264	-	360	*	428	458	532	276	594	142
Xolair	583	6	479	5	552	4	570	3	575	7
Kadcyla	201	-4	198	-3	188	-5	182	-2	189	3
MabThera/Rituxan	314	-15	274	-21	260	-19	227	-19	226	-22
Herceptin	100	-29	91	-37	85	-23	82	-21	73	-20
Avastin	137	-26	133	-25	123	-20	114	-19	114	-9
Alecensa	122	13	106	7	115	14	119	4	127	13
Evrysdi	122	20	124	13	131	19	126	14	124	11
Activase/TNKase	278	-29	288	23	304	9	267	-5	253	-1
Phesgo	87	58	98	62	111	53	111	54	103	27
Polivy	44	65	46	35	78	91	106	161	110	173
Gazyva	94	11	99	32	95	18	103	24	98	14
Ronapreve	-	-	-	-	-	-	-	-	-	-
Lucentis	212	-40	167	-35	132	-55	97	-53	64	-66
Pulmozyme	89	-17	83	-5	75	-16	71	-19	74	-9

\* Over 500%

## 6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022
Ocrevus	267	26	298	11	286	16	293	10	289	11
Hemlibra	199	27	206	27	213	18	218	22	208	8
Perjeta	210	-15	220	1	193	-12	202	0	161	-21
Tecentriq	221	23	195	11	203	7	230	22	217	2
Actemra/RoActemra	200	-14	193	-8	190	0	200	11	192	-1
Vabysmo	18	-	44	-	59	*	82	*	91	406
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	163	-2	154	-6	144	-15	148	-6	131	-17
MabThera/Rituxan	48	-21	51	0	45	-9	44	-11	40	-15
Herceptin	93	-27	97	-17	86	-18	88	-9	82	-10
Avastin	35	-56	30	-45	27	-51	21	-50	20	-43
Alecensa	74	3	73	3	75	5	72	5	72	1
Evryssi	100	116	113	74	128	61	133	35	135	39
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Phesgo	104	61	114	59	126	55	144	47	150	49
Polivy	48	144	40	93	40	76	56	53	37	-21
Gazyva	48	-8	55	25	56	22	63	29	55	18
Ronapreve	-1	-100	-	-100	-	-100	-	-100	5	*
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	23	-13	20	-16	19	-20	18	-18	19	-15

\* Over 500%



## 7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	100	14	92	24	100	19	89	5	92	5
Perjeta	59	3	53	2	56	5	52	6	54	3
Tecentriq	117	6	105	12	109	11	99	5	106	3
Actemra/RoActemra	86	6	77	0	80	5	75	4	79	3
Vabysmo	23	-	21	-	25	299	24	77	28	42
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	30	2	26	-8	26	-17	25	-15	25	-6
MabThera/Rituxan	8	-23	6	-13	7	-15	6	-11	5	-15
Herceptin	11	-28	9	-30	8	-34	7	-35	6	-31
Avastin	112	-21	91	-21	86	-25	73	-28	68	-31
Alecensa	59	7	50	5	57	7	50	5	55	5
Evrysdi	24	83	21	47	24	25	22	21	26	19
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Phesgo	-	-	-	-	-	-	-	-	4	-
Polivy	45	92	51	169	57	194	59	178	60	55
Gazyva	11	-12	8	-35	12	1	8	-18	10	-4
Ronapreve	1,028	313	567	33	-18*	-	-18*	-	-12*	-100
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	1	38	-	18	-	-4	-	34	1	-4

\* Effect of currency revaluation (CHF/JPY) on CHF567m Q1 2023 Ronapreve sales

**8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\***

CHF millions	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022
Ocrevus	138	29	150	32	120	23	128	50	133	22
Hemlibra	114	45	105	38	124	31	103	39	104	14
Perjeta	330	13	384	22	413	18	321	4	323	21
Tecentriq	163	70	113	34	128	23	133	18	187	39
Actemra/RoActemra	94	51	110	10	72	-9	69	20	70	-3
Vabysmo	4	-	7	-	13	**	18	**	31	**
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	96	-3	131	42	134	11	130	41	135	91
MabThera/Rituxan	109	-28	128	-12	111	-14	101	4	99	2
Herceptin	266	-17	280	-7	222	-22	206	-11	204	-12
Avastin	186	-16	162	-19	185	1	165	-5	161	-4
Alecensa	131	13	143	14	139	13	127	10	122	5
Evryssi	80	73	105	189	59	39	79	134	69	18
Activase/TNKase	18	20	14	17	15	8	15	-1	17	-1
Phesgo	23	**	29	232	39	206	45	151	46	196
Polivy	10	86	13	340	28	339	31	422	25	214
Gazyva	38	62	35	27	42	29	39	18	33	2
Ronapreve	21	-81	-	-100	1	-97	-	-100	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	16	-9	24	10	17	-5	15	14	16	18

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%

## 9. Roche Group consolidated income statement for the twelve months ended 31 December 2023

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
<b>Sales</b>	<b>44,612</b>	<b>14,104</b>	-	<b>58,716</b>
Other revenue	1,667	58	-	1,725
Cost of sales	(9,083)	(7,274)	-	(16,357)
Research and development	(12,352)	(1,848)	-	(14,200)
Selling, general and administration	(7,945)	(3,042)	(3,894)	(14,881)
Other operating income and expense	233	173	(14)	392
<b>Operating profit</b>	<b>17,132</b>	<b>2,171</b>	<b>(3,908)</b>	<b>15,395</b>
Financing costs				(996)
Other financial income (expense)				(320)
<b>Profit before taxes</b>				<b>14,079</b>
Income taxes				(1,721)
<b>Net income</b>				<b>12,358</b>
Attributable to				
- Roche shareholders				11,498
- Non-controlling interests				860
<b>Earnings per share and non-voting equity security</b>				
Basic (CHF)				14.40
Diluted (CHF)				14.31

## 10. Roche Group core results reconciliation – Full Year 2023

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
<b>Sales</b>	<b>58,716</b>	-	-	-	-	-	-	-	-	<b>58,716</b>
Other revenue	1,725	-	-	-	-	-	-	-	-	1,725
Cost of sales	(16,357)	548	375	183	-	-	-	-	-	(15,251)
Research and development	(14,200)	230	308	425	-	-	-	-	-	(13,237)
Selling, general and administration	(14,881)	1,335	28	-	-	-	-	-	-	(13,518)
Other operating income and expense	392	(75)	-	591	19	(122)	-	-	-	805
<b>Operating profit</b>	<b>15,395</b>	<b>2,038</b>	<b>711</b>	<b>1,199</b>	<b>19</b>	<b>(122)</b>	-	-	-	<b>19,240</b>
Financing costs	(996)	-	-	-	6	10	-	-	-	(980)
Other financial income (expense)	(320)	-	-	-	-	-	-	-	-	(320)
<b>Profit before taxes</b>	<b>14,079</b>	<b>2,038</b>	<b>711</b>	<b>1,199</b>	<b>25</b>	<b>(112)</b>	-	-	-	<b>17,940</b>
Income taxes	(1,721)	(403)	(44)	(71)	(4)	39	-	-	68	(2,136)
<b>Net income</b>	<b>12,358</b>	<b>1,635</b>	<b>667</b>	<b>1,128</b>	<b>21</b>	<b>(73)</b>	-	-	<b>68</b>	<b>15,804</b>
Attributable to										
- Roche shareholders	11,498	1,626	664	1,123	21	(73)	-	-	68	14,927
- Non-controlling interests	860	9	3	5	-	-	-	-	-	877
EPS - diluted (CHF)	14.31	2.01	0.83	1.40	0.03	(0.09)	-	-	0.08	18.57

## 11. Divisional core results reconciliation – Full Year 2023

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
<b>Pharmaceuticals</b>								
Sales	44,612	-	-	-	-	-	-	44,612
Other revenue	1,667	-	-	-	-	-	-	1,667
Cost of sales	(9,083)	316	241	183	-	-	-	(8,343)
Research and development	(12,352)	155	301	406	-	-	-	(11,490)
Selling, general and administration	(7,945)	721	9	-	-	-	-	(7,215)
Other operating income and expense	233	(80)	-	591	14	-	-	758
<b>Operating profit</b>	<b>17,132</b>	<b>1,112</b>	<b>551</b>	<b>1,180</b>	<b>14</b>	<b>-</b>	<b>-</b>	<b>19,989</b>
<b>Diagnostics</b>								
Sales	14,104	-	-	-	-	-	-	14,104
Other revenue	58	-	-	-	-	-	-	58
Cost of sales	(7,274)	232	134	-	-	-	-	(6,908)
Research and development	(1,848)	75	7	19	-	-	-	(1,747)
Selling, general and administration	(3,042)	124	19	-	-	-	-	(2,899)
Other operating income and expense	173	6	-	-	5	(124)	-	60
<b>Operating profit</b>	<b>2,171</b>	<b>437</b>	<b>160</b>	<b>19</b>	<b>5</b>	<b>(124)</b>	<b>-</b>	<b>2,668</b>
<b>Corporate</b>								
Selling, general and administration	(3,894)	490	-	-	-	-	-	(3,404)
Other operating income and expense	(14)	(1)	-	-	-	2	-	(13)
<b>Operating profit</b>	<b>(3,908)</b>	<b>489</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2</b>	<b>-</b>	<b>(3,417)</b>

## 12. Roche Group consolidated balance sheet

in millions of CHF	31 December 2023	31 December 2022	31 December 2021
<b>Non-current assets</b>			
Property, plant and equipment	21,724	23,075	23,163
Right-of-use assets	1,215	1,133	1,249
Goodwill	9,390	10,820	10,809
Intangible assets	14,828	9,685	12,117
Deferred tax assets	6,882	6,427	5,583
Defined benefit plan assets	1,019	957	1,498
Other non-current assets	1,964	2,238	2,271
<b>Total non-current assets</b>	<b>57,022</b>	<b>54,335</b>	<b>56,690</b>
<b>Current assets</b>			
Inventories	7,749	8,605	7,715
Accounts receivable	11,021	11,606	10,806
Current income tax assets	344	313	320
Other current assets	3,822	3,525	3,755
Marketable securities	5,134	4,776	6,181
Cash and cash equivalents	5,376	4,991	6,850
<b>Total current assets</b>	<b>33,446</b>	<b>33,816</b>	<b>35,627</b>
<b>Total assets</b>	<b>90,468</b>	<b>88,151</b>	<b>92,317</b>
<b>Non-current liabilities</b>			
Long-term debt	(24,809)	(21,391)	(16,076)
Net deferred tax liabilities	(593)	(645)	(628)
Defined benefit plan liabilities	(4,379)	(4,561)	(6,103)
Provisions	(1,059)	(1,111)	(1,442)
Other non-current liabilities	(1,541)	(1,189)	(1,307)
<b>Total non-current liabilities</b>	<b>(32,381)</b>	<b>(28,897)</b>	<b>(25,556)</b>
<b>Current liabilities</b>			
Short-term debt	(4,400)	(3,960)	(15,122)
Current income tax liabilities	(2,257)	(3,187)	(3,002)
Provisions	(1,684)	(2,248)	(2,526)
Accounts payable	(4,325)	(4,556)	(4,637)
Other current liabilities	(12,158)	(13,288)	(13,129)
<b>Total current liabilities</b>	<b>(24,824)</b>	<b>(27,239)</b>	<b>(38,416)</b>
<b>Total liabilities</b>	<b>(57,205)</b>	<b>(56,136)</b>	<b>(63,972)</b>
<b>Total net assets</b>	<b>33,263</b>	<b>32,015</b>	<b>28,345</b>
<b>Equity</b>			
Capital and reserves attributable to Roche shareholders	29,315	27,992	24,489
Equity attributable to non-controlling interests	3,948	4,023	3,856
<b>Total equity</b>	<b>33,263</b>	<b>32,015</b>	<b>28,345</b>

### 13. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2023	FY 2022
<b>Cash flows from operating activities</b>		
Cash generated from operations	22,617	26,030
(Increase) decrease in net working capital	(1,107)	(2,418)
Payments made for defined benefit plans	(743)	(655)
Utilisation of provisions	(1,052)	(1,052)
Disposal of products	-	-
Other operating cash flows	-	-
<b>Cash flows from operating activities, before income taxes paid</b>	<b>19,715</b>	<b>21,905</b>
Income taxes paid	(3,620)	(4,102)
<b>Total cash flows from operating activities</b>	<b>16,095</b>	<b>17,803</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(3,742)	(3,449)
Purchase of intangible assets	(907)	(1,103)
Disposal of property, plant and equipment	173	82
Disposal of intangible assets	-	-
Disposal of products	558	612
Business combinations	(6,220)	(245)
Divestment of subsidiaries	1	1
Interest and dividends received	168	32
Sales of marketable securities	125	148
Purchases of marketable securities	(87)	(271)
Sales (purchases) of money market instruments and time accounts over three months, net	(745)	1,250
Other investing cash flows	33	19
<b>Total cash flows from investing activities</b>	<b>(10,643)</b>	<b>(2,924)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of bonds and notes	8,167	8,442
Redemption and repurchase of bonds and notes	(1,751)	(1,750)
Increase (decrease) in commercial paper	(806)	1,293
Increase (decrease) in other debt	175	(13,683)
Hedging and collateral arrangements	155	(526)
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(770)	(557)
Principal portion of lease liabilities paid	(339)	(405)
Dividends paid	(7,926)	(7,832)
Equity-settled equity compensation plans, net of transactions in own equity	(1,144)	(1,257)
Other financing cash flows	-	-
<b>Total cash flows from financing activities</b>	<b>(4,239)</b>	<b>(16,275)</b>
Net effect of currency translation on cash and cash equivalents	(828)	(463)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>385</b>	<b>(1,859)</b>
Cash and cash equivalents at beginning of period	4,991	6,850
<b>Cash and cash equivalents at end of period</b>	<b>5,376</b>	<b>4,991</b>